FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years - Related Studies - ClinicalTrials.gov

Skip to Main Content

ClinicalTrials.gov

Beta test our new site.

(NLM Technical Bulletin)

Home Search Study Topics Glossary


	Full Text View


	Tabular View


	No Study Results Posted


	Related Studies

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

This study is ongoing, but not recruiting participants.

Study NCT00254410 Information provided by M.D. Anderson Cancer Center

First Received on November 14, 2005. Last Updated on August 24, 2012 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Chronic Lymphocytic Leukemia

Additional conditions recognized in this trial

Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid

More general conditions related to this trial

Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type

Interventions listed in this trial

Fludarabine
Cyclophosphamide
Mitoxantrone
Rituximab
Filgrastim

Additional drug interventions recognized in this trial

Fludarabine monophosphate
Lenograstim
Vidarabine

Sponsors listed in this trial

M.D. Anderson Cancer Center
OSI Pharmaceuticals

Back to top of Main Content